Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.
Journal of comparative effectiveness research(2023)
摘要
To examine benefits of corticosteroids for Duchenne muscular dystrophy (DMD) by age and disease progression. Data from daily steroid users (placebo-treated) were pooled from four phase 2b/3 trials in DMD. Outcomes assessed overall and among subgroups included changes from baseline to 48 weeks in six-minute walk distance (6MWD), timed function tests and North Star Ambulatory Assessment total score. Among 231 patients receiving deflazacort (n = 127) or prednisone (n = 104), observed differences in 6MWD favoring deflazacort over prednisone were significant for patients with relatively older age (≥8-years-old), greater disease progression (baseline timed stand from supine ≥5 s), or longer corticosteroid use (>3 years). Daily deflazacort had greater benefits than daily prednisone particularly among older/more progressed patients.
更多查看译文
关键词
Duchenne muscular dystrophy,clinical outcomes,deflazacort,disease milestones,efficacy,prednisone/prednisolone
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要